Background. The incidence of varicella disease is declining as a result of vaccination, making clinical diagnosis more challenging, particularly for vaccine-modified cases. We conducted a comprehensive evaluation of laboratory tests and specimen types to assess diagnostic performance and determine what role testing can play after skin lesions have resolved.
predictive value of the clinical diagnosis, especially by new physicians with limited experience with varicella. In addition, varicella disease in previously vaccinated persons is relatively common and often highly modified, with lesions that are fewer in number, more transient, and often macular and/or papular rather than vesicular. Laboratory testing is therefore increasingly important for diagnosis of varicella disease and for case confirmation by public health authorities. There is also an increasing need for alternative specimen types for diagnosis of varicella disease, especially during outbreak investigations, which often commence after rashes have resolved.
We evaluated various laboratory tests and specimen types to assess their performance in diagnosis of varicella disease and to see whether they can serve as adjuncts to polymerase chain reaction (PCR) testing of skin lesions for varicella zoster virus (VZV) DNA, which is currently regarded as the most sensitive and specific method. We also explored whether diagnostic performance varied in persons with a history of varicella disease or vaccination.
METHODS

Study enrollment.
During the period from January 2005 through June 2006, we enrolled persons of any age in Philadelphia, Pennsylvania, and New Haven County, Connecticut, who were suspected by physicians and school nurses as having varicella disease. Both sites have had extensive experience with varicella surveillance and have participated in population-based studies of varicella disease and vaccine effectiveness [4] [5] [6] [7] [8] [9] . This study was approved by the institutional review boards of the Centers for Disease Control and Prevention (CDC) and both study sites. Enrollees or their parents or guardians provided informed consent.
Data and specimen collection. Study participants were visited twice by a physician or study nurse experienced with diagnosis of varicella disease and specimen collection. The first visit occurred as soon as possible after rash onset; the second visit occurred ∼2 weeks later. Standard questionnaires were used for enrollee interviews. During the first visit, the study nurses or physicians were asked to rate the clinical certainty of their diagnosis of varicella disease on a 5-point scale (1, unlikely; 5, very likely).
During both visits, we obtained skin lesion, buccal and throat swab, oral fluid, urine, and blood specimens. Using established methods, we obtained samples from each skin lesion type (vesicles, macular and/or papular lesions, and scabs) present [10, 11] . With the exception of urine and blood samples, we collected duplicate specimens whenever possible.
Samples from vesicles, macular and/or papular lesions, and scabs were collected with a slide and/or polyester swab. All samples from lesions were placed in a sealed container and maintained at ambient temperatures.
Buccal and throat swab samples were collected by holding 2 swabs together and gently swabbing the buccal mucosa and the oropharynx (including tonsillar pillars), respectively, for several seconds. Oral fluid was collected by using 2 OraSure sponges (OraSure Technologies) together and gently swabbing the cheeks and gums for several seconds. The sponges were then left in the mouth for an additional minute to absorb oral fluid.
Urine was collected in a standard urinalysis cup. Blood samples were obtained by venipuncture and/or finger-stick, depending on the enrollee's consent. Blood samples obtained via finger-stick were blotted onto 2 filter paper circles (10 mm in diameter).
Laboratory methods. Specimens were tested at the National VZV Laboratory, CDC (Atlanta, GA), using multiple methods.
Serum samples were tested for VZV immunoglobulin (Ig) G using an in-house whole-cell enzyme-linked immunoassay (ELISA); samples that yielded negative or equivocal results were retested using the more sensitive glycoprotein ELISA, as previously described [10] . In-house capture ELISAs were used to detect VZV IgM and IgA antibody [10] . IgG titration was done for patients with both acute-and convalescent-phase venipuncture blood samples, as previously described [10] ; a у4-fold increase in titer was considered diagnostic of disease infection. For acutephase serum samples with detectable VZV IgG, avidity was tested, as previously described, to provide supporting information regarding history of varicella disease [11, 12] . Direct fluorescent antibody (DFA) testing requires intact infected cells and, thus, was performed only on vesicular samples (Chemicon; Chemicon International). Results were interpreted on the basis of the manufacturer's recommendations. Slides with у20 cells were classified as adequate.
DNA samples for PCR testing were extracted and purified using an automated platform (Magna Pure; Roche Diagnostics) [13] [14] [15] and genotyped as wild-type or Oka strain, as described elsewhere [10, 11] . Because VZV is highly cell associated, oral and urine specimens were prepared to concentrate cellular material. Oral fluid specimens were prepared for DNA extraction by soaking collection sponges overnight in phosphate-buffered saline, centrifuging at 400g for 10 min, and adding 200 mL of reconstituted oral fluid to 300 mL of Magna Pure lysing buffer. Urine samples were prepared for DNA extraction by centrifuging for 10 min at 400g, aspirating 200 mL from the tube bottom, and mixing with 300 mL of Magna Pure lysing buffer. Actin was used as a PCR control; specimens with undetectable actin DNA were considered to be inadequate. Real-time Fröster resonance energy transfer PCR protocols targeting 4 vaccineassociated DNA polymorphisms in opening reading frames 38 (69349), 54 (95241), and 62 (106262, 107252) were done as described elsewhere [13] [14] [15] .
Classification of cases. PCR results from a vesicle or scab specimen collected at the first visit was defined as our gold standard used to rule-in or rule-out a diagnosis of varicella disease. Enrollees with a vesicle or scab specimen with a positive PCR result were classified as confirmed varicella case patients; enrollees with a specimen with a negative result were considered non-case patients. If vesicle or scab specimens were not available or if results were discordant, varicella case status was defined as indeterminate, and the participants were excluded from analysis. Case patients were categorized on the basis of prior varicella disease and on vaccination history. Cases in patients with no varicella vaccination or disease history were termed "unmodified varicella cases," and cases in those with prior varicella vaccination were termed "vaccine-modified cases." Prior varicella disease and vaccination were validated by medical chart review. If the reported disease history was inconsistent with serologic results, a hierarchical approach was used to clas-sify prior varicella disease status, with IgG and/or avidity test results as the diagnostic reference standard.
Analysis of sensitivity and specificity. We defined sensitivity for each diagnostic test as the percentage of confirmed varicella case patients (ie, on the basis of our gold standard) who tested positive by the diagnostic assay. Specificity was defined as the percentage of non-case patients (also on the basis of our gold standard) who tested negative by the diagnostic assay. We used results from the first adequate specimen of each type collected to calculate sensitivity and specificity. We calculated 95% exact binomial confidence intervals. SAS software, version 9.1 (SAS Institute) [16] , was used to analyze all data.
RESULTS
Demographic data and clinical and epidemiologic results.
Of 299 patients with suspected varicella disease, 93 (66 from New Haven and 27 from Philadelphia) agreed to participate and were eligible for the study. Ages ranged from 0 to 48 years (median, 10 years), and most patients were white and nonHispanic ( Table 1) . Because of differences in case ascertainment by study site, the proportion of suspected varicella disease cases that were vaccine modified varied by age and race. Of note, no vaccinated case patients had received 11 dose of varicella vaccine. Vesicle or scab lesions sampled from 53 of 93 enrollees tested positive for VZV DNA, including specimens obtained from 20 of 27 enrollees who had no history of varicella disease or vaccination, 3 of 11 who had a history of varicella, 27 of 50 who had been vaccinated, and 3 of 5 whose disease (4 patients) or vaccination (1 patient) status was unknown ( Figure 1 ). Vesicle and scab PCR results for remaining enrollees were either negative (15 of 93) or indeterminate (unavailable or discordant; 25 of 93).
Clinical characteristics of the 53 case patients and 15 noncase patients are shown in Table 2 . Vaccine-modified casestients with vaccine-modified disease had fever, у50 lesions, or vesicles.
Diagnostic performance. Data regarding specimen and test performance are shown in Tables 3-5. Only 3 confirmed case patients had a history of varicella disease (performance was not assessable because of the small sample size).
Among 20 case patients classified as having unmodified varicella disease (ie, they had no history of varicella disease or vaccination), PCR testing of macular and/or papular lesions, cheek and throat swab samples, and oral fluid samples collected during the first visit was 95%-100% sensitive (Table 3 ). Just 4 of 15 specimens were deemed adequate for DFA testing; 3 of these 4 tested positive. High clinical suspicion of varicella disease by clinicians was 100% sensitive. During the second visit, oral specimens were collected from almost all case patients with unmodified varicella disease, and scab, urine, and blood samples were obtained from approximately one-half of them. None of these participants had vesicles, and only 1 had a macular and/or papular lesion at this visit. PCR testing of scab specimens was 90% sensitive; it was considerably less sensitive for oral, urine, and blood specimens, although some samples had positive test results up to 20 days after rash onset.
During the first visit, PCR testing of macular and/or papular lesion, throat swab, and oral fluid samples obtained from 27 enrollees with confirmed vaccine-modified varicella disease was 70%-100% sensitive (Table 4) . Sensitivity did not change by interval between rash onset and specimen collection during the 5 days after rash onset (data not shown). Sensitivity of PCR testing of macular and/or papular lesions also did not vary by lesion number among case patients with !50 lesions (data not shown). There were only 3 patients with vaccine-modified disease with whole-blood specimens. High clinical suspicion of varicella disease was 85% sensitive. At the second visit, we collected oral and urine specimens from almost all enrollees in this group and scab specimens from 14 (52%) of them. Only 1 case patient had a vesicle; it tested negative. PCR testing of scab specimens was 69% sensitive. Sensitivity was low for other specimens, although some samples had positive results up to 17 days after rash onset.
Varicella disease was excluded for 15 patients. We were able to use their results to determine that the diagnostic tests were specific (Table 5 ). Low clinical suspicion of varicella by clinicians was 70% specific.
We did not have sufficient number of participants to assess sensitivity of either clinical or laboratory diagnosis by day number following rash onset. For all enrollees tested positive by PCR, VZV was wild-type.
Discordance in gold standard results. We established PCR results from a vesicle or scab specimen collected at the first visit as our gold standard which to classify varicella case-status. To support this choice, we attempted to collect at least 2 vesicle or scab specimens at the first visit to see whether they yielded concordant results.
At the first visit, we obtained 97 specimens (2-8 per patient) from 20 enrollees with unmodified varicella disease; PCR results for all 97 specimens were concordant-positive. We obtained 13 specimens (2-6 per patient) from 4 enrollees with prior varicella disease; PCR results for specimens from 3 of 4 case patients were concordant-positive. The patient with disconcordant results had 2 vesicles or scabs with negative PCR results and 1 scab with positive PCR results. We obtained 106 specimens (1-6 per patient) from the 29 enrollees with vaccine-modified varicella disease; PCR results from 27 of 29 were concordantpositive. The 2 patients with disconcordant results each had 3-5 vesicles or scabs test positive by PCR and 1 vesicle test negative by PCR. Finally, we obtained 38 specimens (1-5 per patient) from 15 confirmed non-case patients; all PCR results were negative concordant. In total, our gold standard provided discordant results for 3 (4%) of 68 suspect VZV cases.
DISCUSSION
Varicella vaccination rates have reached high levels in the United States [1] . The resulting decrease in the incidence of varicella disease, coupled with its modification among vaccinated individuals, is likely to lead to increasing uncertainty in the clinical diagnosis of varicella and greater reliance on the laboratory testing. To our knowledge, this is the first study to systematically evaluate a wide range of laboratory procedures for their ability to diagnose varicella in both vaccinated and unvaccinated people. We tested specimens collected at the time of rash onset to inform clinicians seeing patients with acute illness, and again 2 weeks after rash onset, to assist public health workers who are often only able to investigate sporadic or outbreak-associated cases after resolution of the illness. We attempted to determine whether alternatives to PCR testing exist when skin lesions are no longer available for sampling. PCR testing of vesicles or scabs sampled during early illness provides sensitive and specific evidence of varicella [17] [18] [19] [20] [21] [22] , and previous studies have revealed it to be considerably more sensitive than shell viral culture or standard culture [18, 19, 23] . This test served as the gold standard for our study. We found that almost all PCR results were concordant, providing reassuring evidence about the performance of our gold stan- a PCR result from a vesicle or scab specimen collected at the first visit was defined as the gold standard and used to classify the disease status of suspect case-patients.
b Of 93 study participants, 12 had equivocal whole-cell enzymelinked immunoassay (ELISA) immunoglobulin (Ig) G results from either the first or second visit. Of the 12 equivocal results, 3 were reclassified as IgG positive, 5 were re-classified as IgG negative, and the remaining 4 could not be classified on the basis of glycoprotein ELISA (gpELISA) results. Among the laboratory-confirmed unvaccinated case patients, there was 1 who was reclassified as having a negative IgG as determined on the basis of the gpELISA result and 1 who could not be reclassified. There were 2 laboratory-confirmed vaccinated case patients with equivocal whole-cell IgG ELISA results, which were re-tested with gpELISA: one was reclassified as having a positive IgG, and the other's results remained equivocal after gpELISA testing. Of the 93 participants, 20 had negative whole-cell ELISA IgG results for specimens obtained during either the first or second visit; all remained IgG negative after gpELISA testing.
c There were 14 unvaccinated enrollees with both disease history information and avidity test results, which were concordant with the exception of a 1-month old infant, who had reported no prior varicella disease history, but had a high varicella zoster virus (VZV) IgG avidity result. The high avidity in this case is likely from maternal antibodies and therefore this enrollee was classified as unvaccinated with no prior disease history. There were 3 vaccinated enrollees with both disease history information and avidity test results. All had no prior varicella disease history, but had high VZV IgG avidity results; their high avidity is likely due to their varicella vaccination. Varicella status for enrollees categorized as PCR +/Ϫ was defined as indeterminate because they were either missing a vesicle or scab sample at the first visit or they had disconcordant vesicle or scab PCR results in the first visit. All but 3 cases were classified as indeterminate because the patients were missing a vesicle and scab specimen at the first visit; the 3 exceptions included 1 unvaccinated patient with a prior disease history and 2 vaccinated patients.
dard. We found that PCR testing of macular and/or papular lesions collected soon after rash onset also yielded sensitive results. These findings are particularly important, because vaccine-modified varicella disease often manifests with macular and/or papular lesions only [3, 24] . Sensitivity did not vary by number of total lesions during rash, suggesting that any available lesions should be adequate. PCR testing of oral specimens was also sensitive, particularly among case patients with unmodified varicella disease. Both skin lesions and oral specimens yielded specific results as well. All tests were less useful 2 weeks after rash onset; skin lesions were not readily available once the illness resolved, and test results for oral specimens were mostly negative.
Other tests were less valuable for diagnosing varicella [10, 17, 25] . DFA requires properly collected specimens and yielded mostly indeterminate results, even in the hands of experienced staff. IgM was insensitive, although one study found IgM to be 75% sensitive among vaccine-modified cases [10] . Although the reason for this discrepancy is unknown, it may be due to the timing of specimen collection; 78% of vaccine-modified cases in our study were sampled 0-3 days after rash onset, whereas 77% of cases in Weinmann et al [10] were sampled at 1-7 days. When detectable, VZV-specific IgM antibody is an indication of recent exposure to the virus, but it may not discriminate between primary infection, reinfection, or reactivation [10, 17] . Documentation of increases in IgG antibody titers requires collection of 2 specimens, making it unsuitable for diagnosing varicella disease during the acute illness. Furthermore, increases in IgG titers may be difficult to demonstrate in people with preexisting titers due to vaccination or previous infection. During primary infection, IgG responses may not be detectable at the acute time-point and are probably still developing 2 weeks after rash onset [26] ; end point titration did not improve our test sensitivity. Urine yielded insensitive results. Although VZV in urine or oral fluid specimens should all be cell-associated, false-negative results could have been possible if some VZV occurred in a cell-free state.
Oral specimens and urine samples do not appear to offer clear advantages for diagnosing varicella disease, particularly because skin lesions can be sampled readily and with minimal invasiveness. However, in select circumstances, such unconventional specimens can serve as useful alternatives, because they are easy to obtain and can sometimes yield positive results after skin lesions have resolved. This might be particularly relevant in the setting of outbreak investigations in which many children need to be evaluated after their rashes have cleared.
Better laboratory tools are still needed to fill this public health need. Among our study participants with unmodified or vaccinemodified varicella disease, clinical diagnosis was 100% and 85% sensitive, respectively. We were able to rule out cases of suspected varicella disease through laboratory testing, allowing us to determine that the specificity of clinical diagnosis was 70%. Our results suggest that clinical diagnosis of varicella can be accurate, even among vaccinated persons, particularly when the clinician is confident about the diagnosis. Scabs, recognized exposure to varicella or herpes zoster disease, and school attendance have been found to support the diagnosis of vaccinemodified varicella disease [27] .
Eleven study participants reported prior episodes of varicella disease, but only 3 had evidence of prior disease. Second episodes of varicella disease have been reported in the literature [28] [29] [30] [31] , including one study suggesting that the proportion of such cases is increasing [31] , perhaps in association with reduced VZV-specific immunity as exposures to varicella decreases or with careful case seeking for vaccine-modified disease. Avidity testing may provide a useful tool to monitor this phenomenon more comprehensively. There were limitations to our study. It was conducted using experienced staff, in communities with clinicians that had participated in prior varicella surveillance activities. The quality of case finding, clinical recognition, and sample collection may therefore have differed from other settings, which could have affected assay performance, particularly for PCR testing of macular and/or papular lesions, for which proper specimen collection is important. Persons with mild modified varicella disease may not have sought medical attention or the diagnosis may have otherwise not been considered.
As the epidemiology of varicella disease changes, it has become increasingly important to test suspected cases to obtain a clinical diagnosis for case management and outbreak investigation and to monitor the impact of the varicella vaccine program. We have shown that PCR testing of skin lesions is highly sensitive and specific for detecting VZV, and oral specimens can play a supporting diagnostic role in certain settings. However, PCR testing is not universally available, and better tests would be useful for public health workers to diagnose varicella disease after transient lesions have cleared. This is particularly important in outbreak situations, in which accurate case ascertainment is critical for evaluating the impact and effectiveness of varicella vaccine. For now, clinicians and public health workers should be encouraged to request PCR testing of suspected cases of varicella disease, and public and commercial laboratories should be encouraged to conduct such testing. Lastly, the research community should be encouraged to develop new methods for diagnosing varicella and ascer-taining recent VZV exposure (eg, the analysis of VZV-specific T and B cells, memory B cells, and activation markers in peripheral blood lymphocytes) in the absence of remaining lesions.
